COYA Coya: EV/EBITDA Multiple

Symbol and logo of brand Coya Therapeutics (COYA)

The EV/EBITDA price chart for Coya Therapeutics, Inc. (COYA) is currently at 0.00. The absence of commercial products is offset by strategic partnerships while T-cell therapies remain under development. In the future, proprietary technologies are expected to ensure stable revenue driven by high demand. Meanwhile, Coya Therapeutics, Inc. (COYA) is minimizing costs by outsourcing production and testing to third-party contractors.

COYA (Coya) Business Value to Operating Income Before Depreciation history from 11/23/2025 to 11/16/2026

Comprehensive metric breakdowns and analytics for Coya Therapeutics (COYA)

- stock price and consensus target price:
Initial company analysis:COYA (Coya Therapeutics)
Product sample of coyatherapeutics.com

The EV/EBITDA multiple compares the total enterprise value, including debt, to operating profit before taxes and amortization, allowing for an assessment of the asset's real value regardless of the financing structure. By analyzing the EV/EBITDA metric of Coya Therapeutics, Inc. (COYA) across a financial timeline, an investor determines the efficiency of the capital expenditures required by Coya Therapeutics, Inc. (COYA) to maintain complex biomaterial logistics while developing treatments for neurodegeneration.

Key competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Inc BIIB|EV/EBITDA Multiple neurocrine.com NBIX|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Axsome|ACAD: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XENE|VKTX (Viking Therapeutics Corp) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation SUPN (Supernus)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Harmony Pharma - Enterprise Value to EBITDA Ratio|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx Pharmaceuticals - EV/EBITDA Multiple|Company Value to EBITDA trevitherapeutics.com|PRAX: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio AVXL (Anavex Life Sciences Corp.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell, Inc.|Company Value to EBITDA Prothena Biosciences PRTA|Enterprise Value to EBITDA Ratio ALEC (Alector Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio Annexon, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros Corporation OMER|NGNE - Enterprise Value to EBITDA Ratio|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VYGR|NMRA: EV/EBITDA Multiple|Scilex Holding Company - Business Value to Operating Income Before Depreciation|TVGN (Tevogen Bio Holdings, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Alpha Cognition|EV/EBITDA Multiple CGTX|IKT - Company Value to EBITDA|EV/EBITDA Multiple SAVA (cassavasciences.com)|Business Value to Operating Income Before Depreciation ASRT|VistaGen Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Ovid Therapeutics OVID|ABOS: EV/EBITDA Multiple|CervoMed Corporation (CRVO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Limited|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CLNN|EV/EBITDA Multiple PEPG|JUNS (Jupiter Neurosciences) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Corp RLMD|EV/EBITDA Multiple Annovis Bio Corporation ANVS|gracetx.com - EV/EBITDA Multiple|Firefly Neuroscience, Inc (AIFF) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics, Ltd. - Business Value to Operating Income Before Depreciation|RVPH (Reviva Pharmaceuticals Holdings) - EV/EBITDA Multiple|MetaVia Inc (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple NRXS|Total Company Value to Operating Income Before Depreciation Ratio Helius Medical Technologies Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization passagebio.com PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|NERV - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Athira - Enterprise Value to Operating Income Before Depreciation Ratio|ADXN: EV/EBITDA Multiple|ALZN (Alzamend Neuro, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|PTIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple KTTA|Enterprise Value to Operating Income Before Depreciation Ratio CRGT|Avenue Therapeutics Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BCLI|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (Chromocell Therapeutics Corp)|ELYM: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation ITCI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Longboard Pharmaceuticals Inc|marinuspharma.com (MRNS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio NKGN (NKGen Biotech, Inc.)|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics, Inc)|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio vigilneuro.com VIGL|WENA: EV/EBITDA Multiple|Company Value to EBITDA Cerevel Therapeutics Inc (CERE)